[HTML][HTML] The Evolving Role of 18F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer
K Shen, B Liu, X Zhou, Y Ji, L Chen, Q Wang… - Frontiers in …, 2021 - frontiersin.org
Positron emission tomography/computed tomography (PET/CT) is widely used in prostate
cancer to evaluate the localized tumor burden and detect symptomatic metastatic lesions …
cancer to evaluate the localized tumor burden and detect symptomatic metastatic lesions …
Metabolic regulation of prostate cancer heterogeneity and plasticity
C Peitzsch, I Gorodetska, D Klusa, Q Shi… - Seminars in cancer …, 2022 - Elsevier
Metabolic reprogramming is one of the main hallmarks of cancer cells. It refers to the
metabolic adaptations of tumor cells in response to nutrient deficiency, microenvironmental …
metabolic adaptations of tumor cells in response to nutrient deficiency, microenvironmental …
A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration
B Wang, C Liu, Y Wei, J Meng, Y Zhang, H Gan… - Clinical Cancer …, 2020 - AACR
Purpose: Tumor heterogeneity and burden, which impact treatment outcome in prostate
cancer, are rarely evaluated using next-generation imaging. Experimental Design: The trial …
cancer, are rarely evaluated using next-generation imaging. Experimental Design: The trial …
GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers
J Wang, W Xu, B Wang, G Lin, Y Wei, M Abudurexiti… - Cancer Letters, 2020 - Elsevier
Castration-resistant prostate cancer (CRPC) displays a higher 18 F-FDG PET SUV max than
hormone-sensitive prostate cancer, which suggests a greater need for glucose metabolism …
hormone-sensitive prostate cancer, which suggests a greater need for glucose metabolism …
GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome
S Meziou, C Ringuette Goulet, H Hovington… - Prostate cancer and …, 2020 - nature.com
Abstract Background Tumour 18F-FDG-uptake is of prognostic value in high-risk and
metastatic prostate cancer (PCa). The aim of this study is to investigate the underlying …
metastatic prostate cancer (PCa). The aim of this study is to investigate the underlying …
Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?
Radiolabelled small molecules for imaging prostate cancer have rapidly emerged over the
last few years with gallium-68-labelled prostate-specific-membrane-antigen-11 (68Ga …
last few years with gallium-68-labelled prostate-specific-membrane-antigen-11 (68Ga …
[HTML][HTML] Lactate as key metabolite in prostate cancer progression: what are the clinical implications?
P Chetta, R Sriram, G Zadra - Cancers, 2023 - mdpi.com
Simple Summary Advanced prostate cancer remains a clinical challenge, requiring novel
therapeutic treatments and biomarkers for patient-risk stratification. From a metabolic …
therapeutic treatments and biomarkers for patient-risk stratification. From a metabolic …
A comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer
A Fourquet, A Rosenberg, E Mena… - Journal of Nuclear …, 2022 - Soc Nuclear Med
18F-DCFPyL, 18F-sodium fluoride (18F-NaF), and 18F-FDG PET/CT were compared in a
prospective cohort of men with metastatic prostate cancer (PCa). Methods: Sixty-seven men …
prospective cohort of men with metastatic prostate cancer (PCa). Methods: Sixty-seven men …
Quantification of metastatic prostate cancer whole-body tumor burden with 18F-FDG PET parameters and associations with overall survival after first-line abiraterone …
New biomarkers for metastatic prostate cancer are needed. The aim of this study was to
evaluate the prognostic value of 18F-FDG PET whole-body tumor burden parameters in …
evaluate the prognostic value of 18F-FDG PET whole-body tumor burden parameters in …
[HTML][HTML] The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer …
M Bauckneht, F Bertagna, MI Donegani… - Prostate Cancer and …, 2021 - nature.com
Background We aimed to test whether the prognostic value of 18 F‐Fluorodeoxyglucose
Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in metastatic …
Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in metastatic …